WW International, known as WeightWatchers, saw its stock soar on new of its new compounded GLP-1 offering. But analysts say ...

A recently released negative study by Novo Nordisk (NVO) on the differences between its own semaglutide and liraglutide ...

Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” ...

In addition to availability, the cost of weight loss drugs like Wegovy and Zepbound is a major barrier preventing many ...

Mounjaro and Zepbound are now out of shortage. This should be good news—but because so many patients are taking compounded ...

Medicare is prohibited by law from covering GLP-1 drugs for weight loss. But many beneficiaries can access the drugs anyway.

Only a fifth of large U.S. companies cover pricey GLP-1 weight-loss drugs like Wegovy and Zepbound in their health insurance ...

When it comes to coverage for the pricey GLP-1 weight-loss drugs Wegovy and Zepbound, only a fifth of large U.S. companies ...

Medicare’s costs could balloon by the low to middle tens of billions of dollars over 10 years due to the cost of covering GLP-1 drugs for obesity.

Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a ...

Fewer than 20% of large employers are covering GLP-1 weight loss drugs like Ozempic, a new KFF analysis shows.